Refanalin for lung preservation and transplantation

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,075,080.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44HL080806-02
Agency Tracking Number:
HL080806
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP, 1050 Stewart Ave., Garden City, NY, 11530
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
053129065
Principal Investigator:
WEIZHONG CAI
(516) 562-1140
WCAI@ANGION.COM
Business Contact:
(516) 326-1200
igoldberg@angion.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting early graft function, graft viability and recipient morbidity and mortality. Marginal donor lungs, are even more susceptible to ischemia-reperfusion injury, and often fail transplantation. Scatter factor/hepatocyte growth factor has significant protective activity in the setting of pulmonary ischemia-reperfusion injury and additionally, favors pulmonary epithelial repair and regeneration. However its clinical use is limited by the logistical difficulties associated with its administration. During our Phase I program, we have identified Refanalin, an organic small molecule scatter factor/hepatocyte growth factor mimetic that improves lung function secondary to ischemia-reperfusion injury, attenuates pulmonary epitheli al death and promotes epithelial regeneration. In a preclinical model of lung cold preservation and transplantation, Refanalin treatment reduced roentgenographic alveolar infiltration, improved pulmonary function and preserved pulmonary microarchitecture. The present Phase II makes an in-depth evaluation of Refanalin efficacy in clinically relevant models of lung transplantation. By attenuating allograft dysfunction and preventing allograft failure, Refanalin can reduce recipient morbidity and mortality. By attenuating ischemia- reperfusion injury in the marginal lung, Refanalin can salvage an otherwise discarded organ, and increase the donor pool. PUBLIC HEALTH RELEVANCE: A small molecule cytoprotective that can be added to the lung preservation solution an d administered to graft recipient has significant clinical potential in lung and other solid organ transplantation.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government